EXEL News and Press, Exelixis Inc. From 04/21/22

Driven by their blockbuster Cabo, Exelixis generated $1.43B in total revenues translating to a 45.3% year-over-year (YOY) increase. For further growth, the company is expanding Cabo's label in multiple ongoing Phase 3 investigations. Aside from Cabo, Exelixis is tinkering with sma...

Exelixis (NASDAQ:EXEL) said it had started dose-escalation for phase 1 trial of its anti-cancer compound, XL114, to treat non-Hodgkin’s lymphoma (NHL), in patients who had received prior standard therapies. The company said the objectives of the study will be to determine the reco...

– XL114 is a CARD11-BCL10-MALT1 pathway inhibitor with demonstrated activity in lymphoma models that are resistant to Bruton's tyrosine kinase inhibitors – Exelixis, Inc. (Nasdaq: EXEL) today announced initiation of the dose-escalation stage of the firs...

Exelixis, Inc. (Nasdaq: EXEL) today announced that Charles Cohen, Ph.D. has notified the company of his decision to retire from the Exelixis Board of Directors. Dr. Cohen will not stand for re-election to the Board at the company’s 2022 Annual Meeting of Stockholders, which h...

It's safe to say that the stock market hasn't had the best year so far. Investors have taken their money out of equities in droves in anticipation of impending interest rate hikes in the U.S. and because of geopolitical tensions. But even amid this turmoil, some companies have performed wel...

– CHMP recommendation follows September 2021 U.S. FDA approval of CABOMETYX in this setting – Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Us...

Gainers: Incannex Healthcare (NASDAQ:IXHL) +28%, GitLab (NASDAQ:GTLB) +12%, NextCure (NASDAQ:NXTC) +5%, Cyxtera Technologies (NASDAQ:CYXT) +4%, Grindrod Shipping (NASDAQ:GRIN) +4%. Losers: Coupa Software (NASDAQ:COUP) -27%, DLocal (NASDAQ:DLO) -13%, Mesa Air (NASDAQ:MESA) -3%, Aurora Inn...

Exelixis (NASDAQ:EXEL) announced on Monday that the company would no longer pursue its planned submission of the supplemental New Drug Application for its cancer therapy, Cabometyx, to the U.S. Food and Drug Administration (FDA). The decision followed an analysis from the phase 3 COSMIC-312 t...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial, which evaluated cabozantinib (CABOMETYX ® ) in combination with atezolizumab versus sorafenib in patients...

The United States economy is growing strongly, outperforming other developed economies. Furthermore, analysts believe the country is well-positioned to weather economic challenges created by the Russia-Ukraine war. So, we think that growth stocks Vertex Pharmaceuticals (VRTX), Fair Isaac (FIC...